# Precision Approaches to Treat Mantle Cell Lymphoma: Integrating Multi-omics Based Models

> **NIH NIH K00** · RICE UNIVERSITY · 2024 · $87,250

## Abstract

Project Summary
Mantle cell lymphoma (MCL) is a rare, incurable form of non Hodgkin lymphoma which is disposed to
therapeutic resistance and relapse. Though rare, MCL is both clinically and genetically heterogenous and
represented by multiple subtypes. It is presently unknown how various genomic features impact the clinical
course of MCL and how these biological aspects contribute to treatment resistance and disease progression. It
is difficult to study the molecular features of MCL due to its rarity and lack of representation in accessible
databases like the cancer genome atlas (TCGA). Additionally, it is currently challenging to integrate -omics
features in precision medicine initiatives due to the vast size of data from sequencing and unclear biological
and clinical relevance of singular mutational and transcriptional features. It is also difficult to study these
features in combination with demographic and other relevant individual features.
In the F99 phase of the proposed dissertation research project, Holly Hill will employ novel analytical and
computational methods to integrate multi-omics datasets in a pooled analysis of MCL patients. These analyses
will include genomics, transcriptomics, epigenomics and features of the clinical exposome. Feature selection
and variable reduction techniques will be used as appropriate. These sub-analyses will identify biological
correlates and generate composite variables which will be used in univariate and multivariate models to
examine clinical outcomes in MCL including drug response and survival.
The KOO phase of the proposed activities will include further investigations into MCL and other cancers utilizing
knowledge gained from the dissertation project (F99). Insights acquired during the F99 phase will also be used
to develop targeted assays that simplify the mutational or transcriptional profiles of MCL into clinically useful
and valid applications. Serial -omics measurements will be integrated into correlative genomics studies and
precision medicine trials which will include sequencing from liquid biopsies or circulating tumor DNA (ctDNA).
The proposed efforts will produce insights into condensing and translating data from -omics studies into the
clinical space. It is hoped that the findings of this study will inform methods suitable for precision medicine trials
and help achieve our long-term objective to personalize therapeutics for individual cancer patients.

## Key facts

- **NIH application ID:** 10990588
- **Project number:** 4K00CA274686-02
- **Recipient organization:** RICE UNIVERSITY
- **Principal Investigator:** Holly Ann Hill
- **Activity code:** K00 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $87,250
- **Award type:** 4N
- **Project period:** 2023-12-01 → 2024-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10990588

## Citation

> US National Institutes of Health, RePORTER application 10990588, Precision Approaches to Treat Mantle Cell Lymphoma: Integrating Multi-omics Based Models (4K00CA274686-02). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10990588. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*